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doi:10.1016/j.jds.2012.01.013Abstract Drug-induced gingival overgrowth is an adverse event associated with three types
of drugs, i.e., anticonvulsants, immunosuppressants, and calcium-channel blockers. It was
shown that the combined use of an immunosuppressant (cyclosporine) and a calcium-
channel blocker increases the prevalence and severity of gingival overgrowth. However, few
reports discussed the effects of the combination of an anticonvulsant (phenytoin) and
a calcium-channel blocker (amlodipine). In this case report, we present an epilepsy patient
who was using both phenytoin and amlodipine, which caused extensive gingival overgrowth.
After periodontal treatment and a gingivectomy, the gingival overgrowth was significantly
reduced. A postoperative drug-substitution regimen and intensive professional care ensured
a stable result 1 year after surgery.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Gingival overgrowth is associated with multiple factors
including inflammation, adverse events, systemic disease,of Stomatology, Division of
i Veterans General Hospital,
istrict, Taipei 112, Taiwan.
w (Y.-L. Lai).
iation for Dental Sciences of the Reand neoplastic enlargement. Drug-induced gingival over-
growth is a common consequence of the administration of
some anticonvulsants, immunosuppressants, and calcium-
channel blockers.1 Although the pathology of drug-induced
gingival overgrowth is not definitively known, these disor-
ders seem to be induced through disruption of homeostasis
of collagen synthesis and degradation of gingival connective
tissues.
It was shown that the combined use of cyclosporine and
a calcium-channel blocker (CCB) increased the prevalencepublic of China. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Preoperative view showing the severe generalized
gingival overgrowth.
86 C.-W. Chang et aland severity of gingival overgrowth compared with mono-
therapy using cyclosporine or the CCB alone.2e5 However,
few reports mentioned the gingival status in those receiving
a combination of phenytoin and a CCB. This article presents
a case of probable synergism with the combined use of
phenytoin and a CCB that caused extensive gingival over-
growth in a patient with epilepsy.
Case report
A woman 67 years of age presented at the Department
of Dentistry in the Hsin-Chu Hospital in Taiwan, with
a complaint of gum swelling around the entire dentition.
The patient’s medical history disclosed epilepsy for more
than 10 years due to left-brain trauma in a traffic accident.
She had taken phenytoin since that time. The patient had
a stroke attack 1 year before and subsequently took
amlodipine in addition to phenytoin.
A clinical examination showed generalized gingival
enlargement. The enlarged tissue covered from one-half to
two-thirds of the crowns (Fig. 1). Excessive spacing of the
anterior teeth was also noted. Probing depths of gingival
pockets were at least 5 mm. The patient had compromised
oral hygiene. Generalized plaque accumulation and gingival
inflammation were evident. A radiographic examination ofFigure 2 Initial periathe posterior teeth revealed 20%w50% bone loss. There
were subgingival caries around Tooth Numbers 27 and 36
(Fig. 2). The diagnosis of this case was drug-induced gingival
overgrowth with plaque-induced chronic periodontitis.
Following scaling and oral hygiene instructions given to
the patient, surgical excision of the overgrowing gingiva
under general anesthesia was scheduled because of the
patient’s disability and uncooperative behavior. During the
surgery, a gingivectomy and gingivoplasty were carried out
using surgical knives as well as electrosurgery, which was
used to delicately shape the gingival contour without
causing active tissue bleeding. In addition, full-mouth
scaling and root planing were performed after gingival
contouring. After the surgery, the caries lesions of Tooth
Numbers 27 and 36 were treated. The gingival contour was
much improved. To prevent gingival regrowth, a plaque-
control program was begun for the patient. The patient’s
physician substituted vaproic acid for phenytoin, and
captopril [angiotensin-converting enzyme (ACE) inhibitor]
for amlodipine. The 1-year postoperative follow-up
revealed no recurrence of gingival overgrowth (Fig. 3).
The overall gingival inflammation had improved, and the
probing depths of the teeth were reduced to 3w4 mm.
The excised tissues were sent for biopsy. Histologic
sections showed thickened epithelium and pseudoepithe-
liomatous hyperplasia (Fig. 4), a large amount of dense
bundles of collagen fibers, and mononuclear inflammatory
cell infiltration (Fig. 5).
Discussion
Drug-induced gingival overgrowth is known to be an adverse
effect of three main types of drugs, i.e., phenytoin, an
anticonvulsant; cyclosporine, an immunosuppressant; and
nifedipine, a CCB, which is widely used to manage cardio-
vascular disorders. The prevalence rate of drug-induced
gingival enlargement was reported to vary: 10%w15% for
phenytoin, 8%w70% for cyclosporine, and 0.5%w83% for
nifedipine.1 Gingival tissue reacts differently to various
types of medication. As an anticonvulsant, phenytoin has
long been used to treat epilepsy, whereas valproic acid is
a new antiepileptic and appears to be as effective as
phenytoin at controlling seizures. In addition, valproic acid
also exhibited a lower occurrence of gingival enlargement.6pical radiography.
Figure 3 One-year postoperative view revealing normal and
stable gingival contour.
Figure 5 Dense bundle of collagen fiber in subepithelium
(hematoxylin & eosin, 10).
Drug-induced gingival overgrowth 87As an immunosuppressant, cyclosporine was the main
choice for organ transplantation in the last two decades.
Tacrolimus is a new-generation immunosuppressant and is
an excellent alterative to cyclosporine due to its lower
incidence of gingival overgrowth and a comparable success
rate in organ-graft survival.7 As a CCB, nifedipine is
extensively used to manage hypertension. Amlodipine is
a third-generation dihydropyridine calcium antagonist that
has similar pharmacodynamic effects as nifedipine.
However, amlodipine is characterized by nearly complete
absorption and slow hepatic biodegradation. Patients
undergoing monotherapy with amlodipine had less gingival
overgrowth than those taking nifedipine.8 A cohort study of
135 renal-transplantation patients demonstrated that the
combined use of cyclosporine and nifedipine caused less
gingival overgrowth (53%) than that in patients treated with
cyclosporine and amlodipine (72%).8
Many studies showed that the combined use of CCBs and
immunosuppressants enhanced the risk and severity of
gingival overgrowth.2e5 Spolidorio and colleagues4 foundFigure 4 Gingival hyperplasia, showing pseudoepithelioma-
tous hyperplasia of the epithelium (hematoxylin & eosin, 10).that the prevalence of gingival overgrowth was 58.3% for
cyclosporine use alone and was 84.3% for the combined use
of cyclosporine and a CCB. Similarly, Greenberg and
colleagues5 reported that the concomitant use of cyclo-
sporine and a CCB exhibited a higher occurrence of gingival
overgrowth (76%) than in those treated with cyclosporine
alone (36%). The synergistic effect when using phenytoin
and cyclosporine caused severe gingival overgrowth in
a kidney-transplant patient.9 However, few reports
mentioned the gingival status related to the combined use
of phenytoin and a CCB, which was demonstrated in this
article. The pathogenesis of extensive gingival overgrowth
following concomitant use of amlodipine and phenytoin in
this patient is not clear. Both phenytoin and the CCB inhibit
the intracellular uptake of calcium. This synergistic inhib-
itory action may have affected the secretory properties of
gingival fibroblasts or the production of collagenase,
subsequently exacerbating the development of gingival
enlargement10 (Table 1).2e5,7e9
The most effective approach to ameliorate gingival
overgrowth is withdrawing or substituting medication. In
this case, valproic acid and captopril (an ACE inhibitor)
were substituted for phenytoin and amlodipine. Gingival
hyperplasia associated with valproic acid seems to be
extremely rare,6 and this drug was proposed as an alter-
native medication in patients with phenytoin-induced
gingival hyperplasia. ACE inhibitors are a group of phar-
maceuticals that are primarily used to treat hypertension
and congestive heart failure. It was suggested that long-
term use of an ACE inhibitor may also limit the degree of
fibrosis within grafts during chronic cyclosporine usage. To
prevent the development of gingival overgrowth, ACE
inhibitors may therefore provide greater benefit than
CCBs.11
Treating the gingival overgrowth lesion itself can be
complicated due to the inflammation superimposed on
fibrotic tissue enlargement. Several investigations indi-
cated that the severity of gingival overgrowth is directly
related to the level of oral hygiene and gingival inflam-
mation. Seymour and colleagues6 showed that bacterial
plaque was a key determinant of the severity of phenytoin-
induced gingival overgrowth. It was also demonstrated
Table 1 Effect of combined drug-induced gingival overgrowth.
Combined
drug
Type of drug Study Type of study Result
CCB þ CsA CsA vs. CCB þ CsA (nifedipine) Thomason2 Cohort study GO: CCB þ CsA > CsA
CsA vs. CCB vs. CCB þ CsA
(nifedipine)
Bokenkamp3 Cohort study GO: CCB þ CsA > CsA
CCB þ CsA (nifedipine vs.
amlodipine)
James8 Cohort study Amlodipine þ CsA (72%) > nifedipine þ CsA (53%)
CCB þ CsA vs. CCB þ Tac Spolidorio4 Cohort study Severity of GO: CsA: Tac: CCB þ CsA:
CCB þ Tac Z 58.3%:0%:84.3%:100%
CCB þ CsA vs. CCB þ Tac Greenberg5 Cohort study Prevalence of GO: CsA: Tac: CCB þ CsA:
CCB þ Tac Z 36%:15%:76%:27%
CCB þ Tac Tac vs. CCB þ Tac Ellis7 Cohort study Severity of GO: Tac: CCB þ Tac Z 8.18%:21.3%
CCB þ CsA vs. CCB þ Tac Spolidorio4 Cohort study Prevalence of GO: CsA: Tac: CCB þ CsA:
CCB þ Tac Z 58.3%:0%:84.3%:100%
CCB þ CsA vs. CCB þ Tac Greenberg5 Cohort study Prevalence of GO: CsA: Tac: CCB þ CsA: CCBþ
Tac Z 36%:15%:76%:27%
PH þ CsA PH þ CsA change to PH þ Tac Hernanadez9 Case report After PH þ Tac: 6 months: GO reduction, 12
months: gingiva no transformation
CCB Z calcium channel blocker; CsA Z cyclosporine-A; GO Z gingival overgrowth; PH Z phenytoin; Tac Z tacrolimus.
88 C.-W. Chang et althat gingival inflammation is a significant risk factor
for phenytoin-,6 nifedipine-,2 and cyclosporine-associated2
gingival overgrowth. Therefore, a preventive plaque-control
program is particularly important for managing drug-
induced gingival overgrowth. To achieve excellent plaque
control, comprehensive oral hygiene instruction was
provided to the patient’s family, and meticulous profes-
sional care was delivered to the patient. The 1-year post-
surgical follow-up revealed healthy gingiva, and there was
no recurrence of gingival overgrowth in the patient.
A case of phenytoin- and amlodipine-induced gingival
overgrowth is presented herein. The patient’s normal
gingival contour was achieved using a gingivectomy. A post-
operative drug-substitution regimen and intensive profes-
sional care ensured a stable result.References
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